-
Markeder
-
Aksjer
Sustainable finance2025 Euronext ESG Trends ReportLes merA data-driven snapshot of how Euronext-listed companies are advancing their Environmental, Social and Governance (ESG) practices.
-
Indekser
Access the white paperInvesting in the future of Europe with innovative indicesLes merThe first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
-
ETF-er
The European market place for ETFsEuronext ETF EuropeLes merInvestors benefit from a centralised market place that will not only bring transparency but also better pricing due to the grouping of liquidity.
- Fond
-
Obligasjoner
European Defence BondsGroupe BPCE lists the first bondLes merFirst financial institution in Europe to issue a bond dedicated to the defence sector
- Strukturerte produkter
-
Derivater
Where European Government Bonds Meet the FutureFixed Income derivativesLes merTrade mini bond futures on main European government bonds
-
Råvarer
- Oversikt
- Quotes snapshot
- Power Derivatives
- Milling Wheat derivatives
- Corn derivatives
- Spread contracts
- Rapeseed derivatives
- Durum Wheat derivatives
- Salmon derivatives
- Levering og oppgjør
- Spesifikasjoner og ordninger
- Commitments of Traders (CoT) report
- Commodity brokers
Building a sustainable and liquid power derivatives market.Euronext Nord Pool Power FuturesLes merEuronext and Nord Pool, the European power exchange, announced the launch of a dedicated Nordic and Baltic power futures market.
-
Ressurser
Designed to help students navigate the complexities of financial marketsEuronext Trading gameLes merJoin the Euronext Trading Game and step into capital markets. Learn from today’s leaders, explore sustainable opportunities, and trade with confidence.
Genomic Vision
Identification
Instrument name
GENOMIC VISION
Symbol
GV
ISIN code
FR0011799907
Exchange / Market
Euronext
Handelssted
Paris
Products family
Stocks
Capitalization compartment
Compartment C
ICB
Biotechnology
Activity description
Genomic Vision est spécialisé dans le développement de tests de diagnostic des maladies génétiques et d’analyse génomique des cancers. Le groupe utilise la technologie du peignage moléculaire qui autorise la visualisation directe des molécules individuelles de l’ADN afin de détecter les variations quantitatives et qualitatives du génome et d'établir leur rôle dans une pathologie ciblée.
Source : Cofisem
Website address
http://www.genomicvision.com
Operation
IPO date
ons 02/04/2014
IPO price
EUR 15.00
IPO type
Initial Public offering
Catégorie
IPO
Price range
EUR 13.50 - 16.50
Capital raised
23